COLL Q4 2022 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$130M+373.7% YoY

Gross Profit

$50M38.4% margin

Operating Income

$12M9.1% margin

Net Income

-$7M-5.6% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+2.1%

Cash Flow

Operating Cash Flow

$66M

Free Cash Flow

$65M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$979M

Stockholders' Equity

$195M

Cash & Equivalents

$174M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$130M	$27M	+373.7%
Gross Profit	$50M	-$1M	+3835.1%
Operating Income	$12M	-$34M	+134.5%
Net Income	-$7M	-$25M	+71.2%

Revenue Segments

Belbuca

$42M32%

Xtampza ER

$35M27%

Nucynta IR

$29M22%

Nucynta ER

$19M15%

Symproic

$5M3%

Other

$320,0000%